Comparing Embolization and Spironolactone for Idiopathic Hyperaldosteronism
Compares adrenal artery embolization with spironolactone in people with idiopathic hyperaldosteronism.
Plain-language title generated from the registry record
Registry title: Superselective Adrenal Arterial Embolization Versus Oral Spironolactone for Treatment of Idiopathic Hyperaldosteronism
Key facts
- Where
- Beijing, Chengdu, and Nanchang, ChinaSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 15 and 60 years old?
Source: NCT07328230, who can take part
Where in China
- Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, ChinaTaking people
- The First Affiliated Hospital of Chengdu Medical CollegeChengdu, ChinaTaking people
- Second Affiliated Hospital of Nanchang UniversityNanchang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chinese Academy of Medical Sciences, Fuwai Hospital
- Trial code
- NCT07328230
- Record updated
- 9 January 2026
- Original description
Idiopathic hyperaldosteronism (IHA) represents about 65% of primary hyperaldosteronism cases. Although mineralocorticoid receptor antagonists (MRAs) are the standard first-line treatment, they are often limited by adverse effects. Superselective adrenal artery embolization (SAAE) has been utilized for IHA over the last decade, yet comparative studies against MRAs are lacking. The objective of this study is to compare the safety and efficacy of SAAE and MRA to determine the feasibility of SAAE in treating IHA.Read full original descriptionShow less
A Prospective Randomized Controlled Trial for Treatment of Idiopathic Hyperaldosteronism: Superselective Adrenal Arterial Embolization Versus Oral Spironolactone
Idiopathic hyperaldosteronism (IHA) represents about 65% of primary hyperaldosteronism cases. Although mineralocorticoid receptor antagonists (MRAs) are the standard first-line treatment, they are often limited by adverse effects. Superselective adrenal artery embolization (SAAE) has been utilized for IHA over the last decade, yet comparative studies against MRAs are lacking. The objective of this study is to compare the safety and efficacy of SAAE and MRA to determine the feasibility of SAAE in treating IHA.
Inclusion: Aged from 15 to 60 with no limits in sex; Patients are diagnosed with primary aldosteronism according to the criteria of the 2016 Endocrine Society guidelines; Sub-typing diagnosis confirmed idiopathic hyperaldosteronism; Patients or their legal representatives have to sign written informed consent approved by the ethics committee.
Exclusion: Hemorrhagic or ischemic stroke, endovascular stent implantation and myocardial infarction within the previous 3 months; Severe contrast agent allergy; Patients with other serious organic diseases cannot tolerate SAAE treatment; Other forms of secondary hypertension; Renal insufficiency with an estimated glomerular filtration rate (based on the modification of diet in renal disease criteria) <45 ml/min/1.73 m², and/or serum creatinine >176 μmol/L；; Unilateral adrenal hyperplasia; Women who are pregnant or planning to become pregnant.